ADVANCED LUNG NON-SMALL CELL CARCINOMA
Clinical trials for ADVANCED LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New trial aims to find best treatment for older lung cancer patients
Disease control Recruiting nowThis phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for STK11 lung cancer: experimental combo enters trial
Disease control Recruiting nowThis phase II trial tests whether adding an experimental antibody called GT103 to the immunotherapy drug pembrolizumab can help people with advanced STK11-mutant non-small cell lung cancer. The study enrolls 28 adults whose cancer has worsened despite prior pembrolizumab treatmen…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for Hard-to-Treat lung cancer? osimertinib trial launches
Disease control Recruiting nowThis phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets tough lung cancer
Disease control Recruiting nowThis early-phase trial tests a combination of two drugs, carfilzomib and sotorasib, in people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation. The study aims to find the safest dose and watch for side effects. About 15 participants wh…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail aims to outsmart lung cancer resistance
Disease control Recruiting nowThis early-stage trial tests a new drug called MRX-2843 combined with the standard targeted therapy osimertinib in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see if the combination can stop tumor growth by blocking key enz…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Common painkiller could boost immunotherapy in advanced lung cancer
Disease control Recruiting nowThis phase II trial tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control advanced non-small cell lung cancer when immunotherapy alone starts to show signs of failing. About 20 adults whose cancer has progressed while on standard immunotherapy d…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Scientists hunt for hidden subtypes of cancer wasting
Knowledge-focused Recruiting nowThis study is observing 800 people with advanced lung, colorectal, or pancreatic cancer to understand why some lose weight and muscle (cachexia). Researchers hope to find distinct subtypes of cachexia, which could lead to better, more personalized treatments in the future. Partic…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC